GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (OTCPK:NGENF) » Definitions » EV-to-Revenue

NGENF (NervGen Pharma) EV-to-Revenue : (As of May. 29, 2025)


View and export this data going back to 2019. Start your Free Trial

What is NervGen Pharma EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, NervGen Pharma's enterprise value is $265.55 Mil. NervGen Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil. Therefore, NervGen Pharma's EV-to-Revenue for today is .

The historical rank and industry rank for NervGen Pharma's EV-to-Revenue or its related term are showing as below:

NGENF's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.47
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-05-29), NervGen Pharma's stock price is $3.84. NervGen Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00. Therefore, NervGen Pharma's PS Ratio for today is .


NervGen Pharma EV-to-Revenue Historical Data

The historical data trend for NervGen Pharma's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NervGen Pharma EV-to-Revenue Chart

NervGen Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial - - - - -

NervGen Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NervGen Pharma's EV-to-Revenue

For the Biotechnology subindustry, NervGen Pharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NervGen Pharma's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NervGen Pharma's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where NervGen Pharma's EV-to-Revenue falls into.


;
;

NervGen Pharma EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

NervGen Pharma's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=265.545/0
=

NervGen Pharma's current Enterprise Value is $265.55 Mil.
NervGen Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NervGen Pharma  (OTCPK:NGENF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

NervGen Pharma's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=3.84/0
=

NervGen Pharma's share price for today is $3.84.
NervGen Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NervGen Pharma EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of NervGen Pharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


NervGen Pharma Business Description

Traded in Other Exchanges
Address
112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.